Oncotarget

Research Papers:

Upregulation of homeobox gene is correlated with poor survival outcomes in cervical cancer

Kyung Jin Eoh, Hee Jung Kim, Jung-Yun Lee, Eun Ji Nam, Sunghoon Kim, Sang Wun Kim and Young Tae Kim _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2017; 8:84396-84402. https://doi.org/10.18632/oncotarget.21041

Metrics: PDF 1273 views  |   HTML 2674 views  |   ?  


Abstract

Kyung Jin Eoh1, Hee Jung Kim1, Jung-Yun Lee1, Eun Ji Nam1, Sunghoon Kim1, Sang Wun Kim1 and Young Tae Kim1

1Institute of Women’s Medical Life Science, Department of Obstetrics and Gynecology, Yonsei University College of Medicine, Seoul, Korea

Correspondence to:

Young Tae Kim, email: [email protected]

Keywords: cervical cancer, homeobox genes, survival, TCGA, biomarker

Received: July 20, 2017     Accepted: August 09, 2017     Published: September 16, 2017

ABSTRACT

HOX family members encode transcription factors crucial for embryogenesis and may be associated with carcinogenesis. Here, we evaluated the expression of 39 HOX genes in cervical cancer by using clinicopathological information and gene expression data of 308 patients from The Cancer Genome Atlas (TCGA) database. Correlations between mRNA expression of HOX family members and clinicopathological variables were explored. Seventy-three (23.7%) patients died during the follow-up period (median, 22.0 months). Overall mortality was significantly associated with advanced FIGO stage, lymph node metastasis, lymphovascular invasion, and increased HOXA1, HOXA5, HOXA6, and HOXC11 mRNA expression. Kaplan–Meier survival analysis revealed that overall survival was significantly shorter in patients with high HOXA rather than low HOXA expression (HOXA1, P = 0.012; HOXA5, P = 0.008; and HOXA6, P = 0.006). Upregulated HOXA1, HOXA5, and HOXA6 expression are significantly correlated with unfavorable overall survival and increased mortality in cervical cancer patients. Therefore, HOXA expression is a potential cervical cancer prognostic indicator.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 21041